コンテンツへスキップ
Merck

SAB3500346

Sigma-Aldrich

抗ACE2抗体 ウサギ宿主抗体

affinity isolated antibody, buffered aqueous solution

別名:

抗ACE2抗体

ログイン組織・契約価格を表示する


About This Item

UNSPSCコード:
12352203
NACRES:
NA.41

由来生物

rabbit

品質水準

結合体

unconjugated

抗体製品の状態

affinity isolated antibody

抗体製品タイプ

primary antibodies

クローン

polyclonal

フォーム

buffered aqueous solution

交差性

mouse, human

テクニック

immunofluorescence: suitable
immunohistochemistry: suitable
indirect ELISA: suitable
western blot: suitable

NCBIアクセッション番号

UniProtアクセッション番号

輸送温度

dry ice

保管温度

−20°C

ターゲットの翻訳後修飾

unmodified

遺伝子情報

human ... ACE2(59272)

詳細

Angiotensin-converting enzyme-2 (ACE2), is a membrane-associated and secreted enzyme, encoded by the gene mapped to human chromosome Xp22.2. Ace 2 is a human homolog of ACE and is expressed mainly on vascular endothelium of heart, kidney, and testis. Ace2 structure comprises a N-terminal PD and a C-terminal collectrin-like domain (CLD).

免疫原

ACE2 antibody was raised against a synthetic peptide corresponding to amino acids near the center of human ACE2.

生物化学的/生理学的作用

Angiotensin-converting enzyme-2 (ACE2) catalyzes the conversion of Ang I to Ang1-9. It might also be involved in maintaining the balance of local renin-angiotensin system (RAS) in heart and kidney. Ace 2 acts as a functional receptor for spike glycoprotein of severe acute respiratory syndrome-coronavirus (SARS-CoV) and the new coronavirus (SARS-CoV-2), which is a causative agent for coronavirus disease 2019 (COVID-19). Downregulated expression of Ace 2 causes cardiovascular diseases.

特徴および利点

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

関連事項

The action of this antibody can be blocked using blocking peptide SBP3500346.

物理的形状

PBS(0.02% アジ化ナトリウム含有)

免責事項

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

適切な製品が見つかりませんか。  

製品選択ツール.をお試しください

保管分類コード

10 - Combustible liquids

WGK

WGK 2

引火点(°F)

Not applicable

引火点(℃)

Not applicable


最新バージョンのいずれかを選択してください:

試験成績書(COA)

Lot/Batch Number

適切なバージョンが見つかりませんか。

特定のバージョンが必要な場合は、ロット番号またはバッチ番号で特定の証明書を検索できます。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Lin Wang et al.
Theranostics, 11(2), 649-664 (2021-01-05)
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide epidemic of the lethal respiratory coronavirus disease (COVID-19), necessitating urgent development of specific and effective therapeutic tools. Among several therapeutic targets of coronaviruses, the spike protein is
Clara Husser et al.
Microorganisms, 12(3) (2024-03-28)
While having already killed more than 7 million of people worldwide in 4 years, SARS-CoV-2, the etiological agent of COVID-19, is still circulating and evolving. Understanding the pathogenesis of the virus is of capital importance. It was shown that in
Elisa Avolio et al.
Clinical science (London, England : 1979), 135(24), 2667-2689 (2021-11-23)
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a broad range of clinical responses including prominent microvascular damage. The capacity of SARS-CoV-2 to infect vascular cells is still debated. Additionally, the SARS-CoV-2 Spike (S) protein may act as a
Shine Varghese Jancy et al.
Biological procedures online, 25(1), 22-22 (2023-07-27)
The entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into the host cell is mediated through the binding of the SARS-CoV-2 Spike protein via the receptor binding domain (RBD) to human angiotensin-converting enzyme 2 (hACE2). Identifying compounds that inhibit
Lai-Keng Loi et al.
Heliyon, 9(12), e22614-e22614 (2023-12-18)
The entry of SARS-CoV-2 into host cells involves the interaction between the viral spike protein and the human angiotensin-converting enzyme 2 (ACE2) receptor. Given that the spike protein evolves rapidly to evade host immunity, therapeutics that block ACE2 accessibility, such

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)